There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

A new analysis of 340B hospital data found that the number of Disproportionate Share Hospitals (DSHs) participating in the ...

Australia's drug approval system is under fire, with critics in the United States claiming it is too slow to approve life-saving medicines.

The Center for Health Information and Analysis would be authorized to collect data on PBMs and issue regulations to better collect information from them and to help the state understand cost ...

An analysis on the state of pharmaceutical drug pricing revealed that, despite rebates, consumers' out-of-pocket costs have grown faster than their insurers' prices.

Pharmaceutical Strategies Group (“PSG”), an EPIC company, published its 2025 Trends in Drug Benefit Design Report, delivering critical insights into how payers are navigating a rapidly ...

Starting Jan. 1, the redesigned drug benefit will operate more like other private insurance policies. Coverage begins after patients pay a deductible, which will be no more than $590 next year.

MA lawmakers send Healey bill to cap some drug costs, regulate pharmacy benefit ... share any of the cost of a generic drug, ... for Pharmaceutical Policy and Analysis within the Health ...

After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. drug cost watchdog has provided a final analysis that includes a ...

Cost–benefit analysis offers a clearer way to communicate the magnitude of costs saved ... cost-effectiveness of hepatitis C testing in Canada,54, 56, 57 and obtained hepatitis C treatment costs from ...